2026-10-01 FDA Warning Letter: Walmart, Inc. Cited for Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
Key takeaway: On October 1, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Walmart, Inc. (MARCS-CMS 736557) identifying three unapproved new drugs sold via www.walmart.com: "HClear for him," "Herstat GST," and "Terragen HG Formula," all marketed for treatment of sexually transmitted infections and genital symptoms. The products violate sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act because they lack FDA approval and are not generally recognized as safe and effective; the FDA states that no over-the-counter drug product for STI treatment has been approved, and reliance on such products may cause individuals to forgo appropriate medical care, risking severe complications.
Argus analysis
# FDA Warning Letter Analysis: Walmart, Inc. – Unapproved Drug Products
**Company and Violations**
On October 1, 2026, the FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Walmart, Inc., identifying three unapproved drug products sold through Walmart.com: "HClear for him," "Herstat GST," and "Terragen HG Formula." These products were marketed to treat sexually transmitted infections and related symptoms, including genital herpes and genital sores. The FDA purchased the products directly from Walmart's website in July 2026 and documented that Walmart fulfilled orders through its Walmart Fulfillment Services platform. The agency emphasized that unapproved STI treatments pose serious public health risks, as consumers may delay appropriate medical care and unknowingly transmit infections to partners.
**Regulatory Citations**
The violations center on sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(a) and § 331(d)), which prohibit introducing unapproved new drugs into interstate commerce. Under 21 CFR 201.128, the products' labeling claims—such as "fast-acting outbreak symptom relief" and "relieves pain and itching"—establish drug intent. The FDA found the products are not generally recognized as safe and effective (GRASE), making them "new drugs" requiring FDA approval. The agency noted that homeopathic formulations receive no exemption from these requirements.
**Response Timeline and Industry Implications**
Walmart had 15 business days from receipt to submit a written response to FDAAdvisory@fda.hhs.gov (reference 760337), detailing corrective actions and documentation. Compliance officers in e-commerce and marketplace operations should monitor whether Walmart faces follow-up enforcement actions, including potential seizures or injunctions. Similar retailers managing third-party marketplace sellers should review their vetting processes for drug products and ensure fulfillment operations include compliance screening for unapproved pharmaceutical claims.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Walmart, Inc. MARCS-CMS 736557 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name John Furner Recipient Title President and CEO Walmart, Inc. 702 SW 8th Street Bentonville , AR 72716-6299 United States HWSCSAFETY@wal-mart.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 736557 To John Furner: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of drug products that were purchased on your website, www.walmart.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “HClear for him,” “Herstat GST,” and “Terragen HG Formula” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during review of the product labeling of products purchased on your website www.walmart.com in July 2026. FDA purchased, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” through your website, and these products were introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services. 1 Based on our review, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) a…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Walmart, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Walmart, Inc. as of 2026-10-06. Argus ingests new FDA enforcement records daily.
- What FDA violations was Walmart, Inc. cited for?
- The FDA Warning Letter to Walmart, Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
- When did FDA issue the warning letter to Walmart, Inc.?
- FDA issued the letter (MARCS-CMS 736557) on 2026-10-01 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to Walmart, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/walmart-inc-736557-10012026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-10-01 FDA Warning Letter: Walmart, Inc. Cited for Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-walmart-inc-2026-10-01-unapproved-drug
"2026-10-01 FDA Warning Letter: Walmart, Inc. Cited for Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-walmart-inc-2026-10-01-unapproved-drug.
Argus HQ Research. "2026-10-01 FDA Warning Letter: Walmart, Inc. Cited for Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 9, 2026. https://argushq.ai/fda/warning-letter/fda-wl-walmart-inc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_walmart_inc_2026_10_01_unapproved_drug_2026,
title = {2026-10-01 FDA Warning Letter: Walmart, Inc. Cited for Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-walmart-inc-2026-10-01-unapproved-drug},
note = {Accessed: October 9, 2026}
}